Bearing in mind this was only 50 people, there were allowed to stay on their drug of choice, it was only for 8 weeks, they started at 4.5mg (side-effects during that short period might outweigh any benefits), the questions are subjective, we can't see the raw data, etc ....:

A randomised, placebo-controlled, crossover-design study of the effects of low dose naltrexone on Multiple Sclerosis Quality of Life Inventory (MSQLI54)

N. Sharafaddinzadeh, D. Kashipaza, A. Mogthaderi (Ahwaz, Zahedan, IR)

Objective:

Multiple sclerosis (MS) significantly affects the quality of life (QoL) of patients. The use of low doses of naltrexone (LDN) for the treatment of MS enjoys a worldwide following among MS patients. There is overwhelming anecdotal evidence about beneficial effects of LDN on relapse reduction and disability and in general patients treated with LDN report improvements in a sense of well being, fatigue, as well as bowel, bladder and sexual function.
.........

Conclusion:

LDN is not higher than placebo in improvement of the scales and Physical or Mental Health composite scores of the MSQOL54. Thus LDN has no treatment effect on the QoL of MS patients.

http://registration.akm.ch/einsicht....E_ID=2&XNKONGR...

Here's the link to the assessment method/questionaire:

http://www.nationalmssociety.org/for...cal-study-meas...



Cherie